I
Ian D. Pavord
Researcher at University of Oxford
Publications - 654
Citations - 55329
Ian D. Pavord is an academic researcher from University of Oxford. The author has contributed to research in topics: Asthma & Sputum. The author has an hindex of 108, co-authored 575 publications receiving 47691 citations. Previous affiliations of Ian D. Pavord include John Radcliffe Hospital & University of Warwick.
Papers
More filters
Journal ArticleDOI
Two Lovely Black Eyes; Oh, what a surprise!
Ian D. Pavord,Andrew Bush +1 more
TL;DR: The authors recommend jettisoning ACOS, which may be characterised by a COPD-like systemic inflammatory profile but may be neutrophilic, eosinophilic or mixed; and bronchodilator reversibility fails to distinguish anything from anything else.
Journal ArticleDOI
The BREATHE study: Breathing REtraining for Asthma - Trial of Home Exercises. A protocol summary of a randomised controlled trial
Anne Bruton,Sarah Kirby,Emily Arden-Close,Lynda Taylor,Frances Webley,Steve George,Lucy Yardley,David Price,Michael Moore,Paul Little,Stephen T. Holgate,Ratko Djukanovic,Amanda J Lee,James Raftery,Maria Chorozoglou,Jenny Versnel,Ian D. Pavord,Mark Stafford-Watson,Mike Thomas +18 more
TL;DR: This research aims to demonstrate the power of data-driven, evidence-based decision-making to improve the quality and efficiency of medical treatment for asthma in patients.
Journal ArticleDOI
Balancing the needs of the many and the few: where next for adult asthma guidelines?
TL;DR: In this paper, the authors proposed a combined approach for the diagnosis and management of asthma, in which treatment decisions are driven by objective assessment of key treatable mechanistic traits, rather than using either a population-based or personalised approach.
Journal ArticleDOI
Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma
TL;DR: Both treatments led to similar control of eosinophilic airway inflammation, although PEF and symptom control were better with SFC.
Journal ArticleDOI
Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma
TL;DR: In this paper , the authors summarized the key efficacy data from phase 3 trials, discussed indirect comparisons, and suggested an algorithm for choosing the most appropriate biologic to start with and the first choice to switch to.